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cMonitoring and Evaluation Tool
The findings and conclusions in this monitoring and evaluation tool are those of the authors and do 
not necessarily represent the views of the Centers for Disease Control and Prevention.
This monitoring and evaluation tool was developed by the International Emergency and Refugee 
Health Branch of the U.S. CDC (Janet T. Ousley, MPH, and Susan Temporado Cookson, MD, 
MPH) and the International Rescue Committee (Wendy Venter, MD, MPH). The health education 
component was developed and funded by the Rollins School of Public Health of Emory University 
in Atlanta, GA, USA as part of thesis work. 
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1The Purpose of This Tool
Why this tool? 
This tool is designed to support the effective monitoring and evaluation (M&E) of tuberculosis 
(TB) control programs in refugee camps and other settings located in resource-poor areas. 
Although TB control is not considered a part of responding to the acute stage of a humanitarian 
emergency, TB among refugees and other migratory populations is an important public health 
problem that has been recognized for some time (1,2). As more conflicts become protracted 
and more camps become long-term settlements, the necessity of quality TB control programs 
increases.
Why is this tool important?
An M&E framework is an integral part of quality programming. Although some resources exist 
for evaluation of different elements of healthcare systems and TB control programs, and should be 
used (in particular reference 1), none were found that examine the whole TB control program nor 
were basic, practical and user-friendly (3). This tool is meant to be inclusive and easy to use. 
Who should do the evaluation using this tool?
Given that the setting of these TB control programs is in post-conflict, resource-limited, and 
refugee settings, the evaluators should be representatives of the implementing partner that is 
providing healthcare services or the United Nations High Commissioner for Refugees (UNHCR). 
It is preferred that evaluators be from national or regional headquarters, rather than those directly 
providing healthcare services, to help limit bias.
Who should also use this tool?
This tool is primarily intended to improve performance of medical and laboratory refugee camp 
staff or others in post-conflict or resource-limited settings who plan, organize, conduct, and 
supervise TB activities. Therefore, this tool can be a helpful reference for program staff to improve 
programming between evaluations in these and other resource-limited types of settings. 
Why was it developed?
On June 21, 2007, during a priority-setting meeting with the United Nations Children’s Fund 
(UNICEF), the International Rescue Committee (IRC) asked the Centers for Disease Control and 
Prevention (CDC), International Emergency and Refugee Health Branch (IERHB) to develop tools 
to evaluate IRC’s TB control programs. This tool was designed over the following months and 
then piloted in northeastern Kenya at five TB control programs in June-July 2008 and February 
2009 and in central Kenya at three TB control programs in February 2009.
Where can I get more copies of the tool?
The tool is available for downloading at http://www.cdc.gov/nceh/ierh.
For a copy of the tool on CD ROM, please e-mail: IERHB@cdc.gov. Please include your name, 
affiliation, mailing address, and a local telephone number.
 
2Explanation of This Tool
What is in this tool?
The evaluation tools are broken down into four components:•	
Laboratory—acid fast microscopy•	
Health education—at time of admission and during treatment•	
Clinical—case management and treatment•	
Data management and logistics—statistical evaluation of laboratory activities and •	
program performance. 
Each component has three parts:•	
Evaluation worksheets for the evaluator to complete •	
Scoring guide that includes a comments and recommendations section•	
Explanation worksheet of the importance of each item scored.•	
References and Resources:•	
Appendices: •	
Posters with key messages for sputum collection and health education•	
Patient charter to use at time of admission•	
Program implementation tool•	
Each of the four components of this tool should be printed and the responsible person should 
review the worksheets before starting. 
Further explanation of the three parts 
Each component has three parts—all are important. 
The evaluation worksheeta.  is a list of numbered items. After each item the evaluator 
should write the score. Extra copies of worksheets can be printed from the companion 
CD-ROM or the online tool. The importance of each numbered item is explained in 
the explanation worksheet. Note if an item is not applicable (N/A) or not evaluated 
(N/E) for that worksheet this item score should be subtracted from the total for that 
worksheet. Please notice that worksheets may have multiple pages. 
The guidelines from the National TB Program (NTP) in the host country and the 
refugees’ country of origin should be followed and used as references. All evaluations 
should be done in close collaboration with the NTP and UNHCR. Although, all 
components are critical to a well functioning program, the TB control program may put 
greater emphasis on some components compared with others.
The scoring guideb.  has information on how to score and rate each part. Each item on 
the worksheet has a maximum point value listed after the item number. Partial points 
can be given for some items; some of those reduced points are specifically indicated. 
If an item is not applicable (N/A) or not evaluated (N/E) for that worksheet this item 
score should be subtracted from the total for that worksheet. All the item points must be 
added together to produce an overall score and rating (excellent, good, poor or failed) 
for the component. These scores should only be used as a guide; local constraints and 
3resources may dictate different scores, ratings, and intervals of re-assessment. The 
overall rating suggests how long the program can go without further evaluation and 
highlights strengths and weaknesses of that component of programming. The scores 
(suggested or locally adapted) of sub-sections of each component are important to 
share with the program because these components cover a broad range of topics and 
different sub-sections may have different levels of competencies. 
Within the scoring guide is the Comments and Recommendations section where the 
evaluator can specify deficiencies as noted by partial point values and leave concrete 
recommendations. If major deficiencies are observed in any component or sub-
section during the evaluation, the evaluator should intervene to improve the 
program where needed. 
The explanation worksheetc.  as mentioned above accompanies the evaluation 
worksheet and each numbered item is explained. The explanation worksheet also 
contains numbered references that can be found in the reference section. These 
additional references provide additional guidance and some training resources. Please 
notice that explanation worksheets, as the evaluation worksheets, may have multiple 
pages. 
Evaluation team, timing, and duration
The evaluation is best carried out by a team of evaluators who each have expertise in the field 
he or she is assessing. A laboratorian should evaluate the laboratory evaluation component; a TB 
clinician or expert with knowledge of the clinical-care side of TB treatment should evaluate the 
clinical and reporting components. Health education can be done by either a clinician familiar with 
TB programs or an expert in the area of behavior change communication. 
This tool is designed to be used by both overseeing organizations as an evaluation, and by project 
managers and staff as a tool to improve program quality. When visiting a site, the evaluator from 
the overseeing organization should notify the clinic or TB program to be evaluated so the staff can 
prepare for the arrival of the evaluation team. This is especially important for assessing the health 
education and clinical components of the tool because several patient encounters will need to be 
observed. Program managers and staff can also use the evaluation as a tool to improve the quality 
of their programs.
When notifying staff of an evaluation, explain that the team will be largely observing them 
perform their normal activities. Although staff may be asked some questions, they should attempt 
to function according to their standard daily routines.
Lastly, this tool is not meant to be a comprehensive document. As always, guidelines from the 
World Health Organization (WHO) and NTP in the host country and the refugees’ country of 
origin should be followed and used as references. To keep the tool simple and user-friendly, the 
authors designed it to be completed by two evaluators in an 8-hour day. Local IRC healthcare staff 
completed this M&E tool in an 8-hour day during the pilot process. 
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5Component 1: 
Laboratory Evaluation–Acid-Fast Bacilli 
Microbiology (AFB) Tool
Why the laboratory component of tool?
Laboratories form the foundation for diagnosing TB. A well functioning laboratory plays a crucial 
role in TB control. By responding quickly and providing quality service, the laboratory will enable 
early diagnosis, hence decreasing spread, ensuring appropriate treatment, and minimizing possible 
complications, including death (4).
Who should do this evaluation?
The evaluator needs to have a good understanding of acid-fast bacilli (AFB) smear microscopy 
and good laboratory practice (GLP). Methods assessed include specimen collection, smear 
preparation, acid-fast stain procedure, reading, and reporting. The evaluator must understand 
appropriate methods and ensure they are being followed. The use of standard laboratory reference 
texts is encouraged and should be observed (4,5). As always, guidelines from the World Health 
Organization (WHO) and National TB Program (NTP) in the host country and the refugees’ 
country of origin should be used and followed. 
Further explanation of tool
There are 3 parts: 
Evaluation worksheet for evaluator to complete1. 
Scoring guide that provide suggested scores, rating, and comments and 2. 
recommendations section
Explanation worksheet that explains importance the of each item scored, including 3. 
references
In completing the evaluation worksheet, the evaluators should watch three to five patients coming 
for various stages of treatment. The point values are assigned from the experience gained during 
the pilot testing and are only suggestions. If you, as the evaluator, believe the scoring should 
be different that is appropriate, your experience along with the tool should direct your scoring. 
Resulting scores (suggested or locally adapted) of sub-sections of this component would be 
important to share with the program because the component covers a broad range of topics and 
different sub-sections may have different levels of competencies. In addition, you may want to 
give partial points. Partial item point values should be explained and recommendations given in 
the Comments and Recommendations section after the score guide. If major deficiencies are 
observed in any sub-section during the evaluation, the evaluator should intervene to improve the 
program where needed.
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7Item 
No.
Point  
Value Description (explanations of these items are on the next sheet)
Suggested 
Score
Record Keeping: Evaluator Observes
1 4
Laboratory log/register is legible (dates of collection, quality of sputum 
sample [i.e., saliva], and results) (Give 1 point each for legible dates, 
sputum quality, and smear results)
2 3 Slides labeled permanently with identification number or patient’s name (if frosted, may use pencil)
3 2 Lab uses one result form per patient and labels form with identification number or name (Give 1 point each for each element)
4 2 Lab keeps smears for at least 3 months (one quarter) and stores them appropriately (Give 1 point for each element)
For item 5: Arbitrarily select 3 different pages of register (preferably from different months), average 
each page for percentage of samples that were saliva, then take average of the 3 pages. If <=10% 
saliva, give 5 points; if 11%-20%, give 4 points; if 21%-30%, give 3 points; if otherwise, give 0 points. If 
specimen quality not indicated in register/log, ask separately, 3 different staff (if possible), what percent 
of accepted specimens are saliva and average the three percentages. 
Indicate the source of information of this worksheet (√ the box):    q register     q staff
5 5 Lab encourages sputum, not saliva
Sputum Collection: Laboratory staff
6 4 Adequate supply of clean sputum containers with wide mouth and screw top (enough for 3 months of patients)
7 4 Tell patients how to give adequate sputum specimen (see Appendix A)
8 4 Obtain at least one morning sputum (Ask technician to explain sputum collection and timing; do not ask yes or no questions)
9 4 Collect sputum outside away from others (Ask to see location to ensure away from others)
Smearing Method Measures: Laboratory staff
10 2 Uses new, clean slides and have an adequate supply (enough for 3 months of patients)
11 2 Uses clean applicator (stick, pipette, or wire loop [if loop, remove sputum from prior specimen before flame]) for smearing 
12 2
Air-dry slide (Ask the laboratory technician about drying times, do not ask 
as yes or no question)
13 2
Heat-fix slide (with flame or slide warmer to 65-75°C) (Ask the technician 
whether heat fixing is performed. If yes, ask him or her to explain what is 
done [do not ask as yes or no questions but ask for his/her explanation of 
process])
For items 14-16: Arbitrarily select 10 different stored slides (preferably from different months and at 
least 5 different months). If 9-10 slides meet criteria below, give full points; if 7-8 slides meet criteria,  
give 4 points, if 5-6 slides meet criteria, give 3 points; if otherwise, give 0 points.
14 5 Uses appropriate smear size (1-2 cm x 2-3 cm)
15 5 Uses appropriate evenness (even throughout)
16 5 Uses appropriate thickness (once dry, able to read print through thick film at 4-5 cm)
Part 1: Laboratory Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
Write point score in last column if item passed. Write “0” if item failed. Write N/A if “not 
applicable” or N/E if “not evaluated.”
8Item 
No.
Point  
Value Description (explanations of these items are on the next sheet)
Suggested 
Score
Stain/Reagent Preparation: Laboratory staff
For item 17: Arbitrarily select 5 positive slides (preferably from different months and at least 3 different 
months). If all good, give 4 points;  if 4 good, give 2 points; if 3 or less, give 0 points. NOTE: some slides 
for items 14-16, might be appropriate for item 17
17 4 Stain the slides so AFB are not faded, even after 3 months (AFB stain red)
18 2 Uses stains without precipitate (probably need to assess by examining slides or filter stain). Filtering stain before use can reduce precipitate.
19 4 Uses reagent grade stains (commercial or prepared on site)
20 1 Stores stains at room temperature and away from bright light or heat source (Give ½ point for each element)
If stains prepared on site, answer items 21-25, then skip to 27
21 1 Uses colorless or white crystal phenol and store it in refrigerator or cool area (Give ½ point for each element)
22 2 Uses clean water (preferably distilled, not tap water) 
23 1 Uses balance to weigh 0.1 gram of stain powders
24 4 Uses approved stain formulas
25 1 Records dates of when stains prepared and determines expiration date
If commercial stain used, answer items 26
26 9 Uses commercial stains within expiration date
27 2
Uses stains (commercial or prepared on site) within 12 months of opening/
preparing (preferably within 6 months) (look for record of date when the 
stain was prepared or opened [usually on bottle])
Staining Procedure: Laboratory Staff
28 5 Uses approved staining procedure 
29 3 Uses approved times 
30 2 Uses timer for staining procedure
31 1 Stains individual slides to prevent cross contamination
32 1 Changes solution in bottles used to stain slides every 2 weeks and records change (Give ½ point for each element)
Microscopy and Reading: Laboratory Staff
33 2 Has 100X magnification (plus 10X eye piece)
34 1 Uses clean oil for slide and remove oil from slide before storing with absorbent paper (reduces risk of fungus) (Give ½ point for each element)
35 4
Reads each slide for 5 minutes or 100-150 fields (Ask technician amount 
of time needed to determine slide is negative; do not ask yes or no 
questions. If only observed for 2 minutes, at 100x oil immersion before 
reporting as negative, give 2 points)
36 2 Uses microscope in good working order, i.e., has mechanical stage that moves freely in both axes and well maintained
37 1
Has microscope area with appropriate lighting (good ambient light on 
cloudy days) and sufficient seating space and without distraction or 
vibration (Give ½ point for each element)
38 3 Uses positive control smear at least every week and after new reagent (Give 2 points, if only every two weeks)
39 1 Uses negative control smear at least every week and after new reagent
40 4 Performs external proficiency testing and results observed by evaluator  (If no results observed, give 0 points)
41 1 Processes >15 specimens each week (about 65 each month)
42 2 Uses internationally accepted grading system for reporting results
43 1 Performs second reading on all positive slides
44 1 Reports results within 24 hours from specimen receipt
Part 1: Laboratory Evaluation Worksheet
9Item 
No.
Point  
Value Description (explanations of these items are on the next sheet)
Suggested 
Score
Safety Measures: Laboratory 
If specimen not centrifuged, answer 45 (Give 1 point) and skip to 47
45 1 Does not centrifuge specimen
If specimen centrifuged, answer item 46
46 1 Dilutes specimen to be centrifuged with equal volume of 5% Na hypochlorite 
47 2
Uses biological safety cabinet (BSC). If no BSC, performs smear 
processing in separate area with good ventilation (open window) (Give 1 
point for good ventilation)
48 2 Has well ventilated airflow through laboratory from less-contaminated to more-contaminated areas 
49 1.5
Has a hand washing facility with soap (Without soap, give 1 point) (Ideally, 
evaluator will observe hand washing technique with brisk rubbing of one 
hand over the other)
50 4
Disposes of contaminated material appropriately (especially sputum and 
used smear-making materials) (Need to see incinerator, area of burning or 
burial)
51 2 Cleans bench tops before and after smear preparation and immediately after any spills 
52 1 Restricts access to laboratory 
53 1 Stores flammable reagents in flammables storage cabinet
54 1 Has standard operating procedures readily available in laboratory 
55 1 Uses standard operating procedures
56 1 Performs administrative laboratory work in separate room from processing
57 0.5 Provides continuing education training program for laboratory personnel
58 0.25 Provides proof of training (degree, certification, license or credit)
59 0.25 Provides annual chest X-ray (or tuberculin skin testing) for laboratory personnel
Cultures: Laboratory
60 4.5 Has access to cultures and drug sensitivity testing (DST), at least for relapsed or continued smear-positive patients
A
Score Achieved 
(add score achieved for items 1-22)
B Value of All N/A OR N/E Responses
C
Suggested Total Score Possible
(65 points possible minus value in line B, above)
Part 1: Laboratory Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
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Part 2: Laboratory Scoring Guide
Suggested Score Guide
Total Score from previous page (Line A)
Total Score Possible from previous page (Line C)
Rating 
If Line C=135, use RANGE below; if TOTAL POSSIBLE POINTS <135, use  PERCENTAGE
Percentage 
Line A divided 
by Line C 
(A/C)*100
Range 
Use if Line 
C=135
Rating Suggested Time Until Next Assessment
>=85% 115-135 Excellent Needs assessment in 12-18 months
70-84% 95-114 Good Needs assessment in 9-11 months
50-69% 68-94 Poor Needs assessment in 6-8 months
<=49% <=67 Failed Needs assessment in 2-5 months
Comments and Recommendations (give item no.)
Site     Country     Date
                 dd/mm/yy
11
Part 3: Laboratory Explanation Worksheet
Item  
No. Explanation
Record Keeping
1-4
Good laboratory practices to reduce risk of confusing slides of different patients are labeling 
and keeping slides and records for at least 3 months. National TB (NTP) Programs usually 
provide request forms; if not, the program is responsible for making its own. Slides must be 
stored appropriately, preferably in slide boxes. If slides boxes are not available, store with 
tissue paper between each slide.
5
Examine sputum for thick, mucoid quality, pieces of purulent material, blood, and volume 
(3-5 mL for a good specimen) (3). Clear saliva and nasal discharge are not suitable—request 
repeat specimen, if possible (but even saliva can yield positive result).
Sputum Collection
6 The use of dirty sputum containers increases risk of artifact on smear. A wide-mouth opening and screw-cap container will minimize risk of contaminating outside and top, if leakage occurs.
7-8
Three early mornings sputum samples give highest yield of obtaining a positive smear. For 
practical reasons, this might not be feasible or followed by NTP guidelines. Because of 
laboratory workload in countries where external quality assurance exists, two sputum samples 
(one morning) are now endorsed by WHO (6). Instructions to patients may be given by lab or 
clinical staff; either way, specific instructions need to be given (see Appendix A)
9 Minimize risk to other persons; this procedure has greatest exposure risk to laboratory personnel.
Smearing Method Measures
10 Reduce risk of artifact leading to interpreting result as positive finding (false-positive result).
11 With applicator, collect pieces of thick, purulent material.
12-13
Do not dry smear with sunlight or ultraviolet (UV) light. To keep smear on slide, heat fix air-
dried smear to slide by passing slide with smear side up 2-3 times over flame for 2-3 seconds 
or by placing slide on 65°-75°C electric slide warmer for >2 hours. Do not leave the slide in an 
unprotected area where it could be damaged.
14-15 Smear size (1-2 cm x 2-3 cm), thickness (once dry, able to read print through thick film at 4-5 cm), and even across whole smear.
Stain/Reagent Preparation
17 Color retention of white cells and AFB are indications of quality of stain/reagent.
18 Increase quality of stain and reduce risk of artifact—dirt or precipitate can lead to false-positive result. Probably need to assess by examining slides or filter stain.
19 Use only reagent grade stains.
20
Reagents must be stored at room temperature or precipitates may form, leading to false-
positive result. Reagents must be kept in the dark and away from bright light to ensure they do 
not break down. Place them in a cabinet or in brown bottles away from bright light.
If stains prepared on site, answer items 21-25, then skip to 27
21
Phenol for making fuchsin-phenol stain must be colorless or white crystal. Brown-tinted or 
liquid phenol is unacceptable. It must be kept in a cool, dark place (preferably a refrigerator) to 
remain white crystal. Phenol maintained at room temperature might degrade.
22 To reduce risk of artifact (environmental mycobacteria), use freshly prepared distilled/ deionized water for staining reagents.
23 Need calibration weight to appropriately know and measure quantities for stain reagents.
24-25 Only approved formulas should be used (4). Good laboratory practice requires all stain reagents be dated at time of preparation. From preparation date determine expiration date.
If commercial stain used, answer item 26
26 Chemical stock containers should be dated when received and when first opened.
27 Use prepared staining reagents within 6-12 months of preparation and commercial stains within 6-12 months of opening (but not after expiration date).
12
Item  
No. Explanation
Staining Procedure
28
Fuchsin-phenol must be applied, heated until steaming, then rinsed with tap water and 
drained; decolorized with acid-alcohol (25% sulfuric acid or 3% hydrochloric acid), then rinsed 
with tap water and drained; and methylene blue applied, then rinsed, drained, and dried at 
room temperature.
29
Times may vary, one suggestion:
Fuchsin-phenol for 5-10 minutes, then rinsed; •	
Acid-alcohol for 2-3 minutes, then rinsed; and •	
Methylene blue for 1 minute, then rinsed. •	
30 Too difficult to ensure appropriate times without a timer. Inappropriate times will lead to false answers.
31-32
Staining jars should not be used because of cross-contamination. Best practice is to stain 
slides individually. The staining bottles should be changed every 2 weeks and documented. 
Good laboratory practice (GLP) should include maintenance and cleaning of equipment. 
Microscopy and Reading
33 Use 100X magnification (plus 10X eye piece) to scan smear and count any AFB seen.
34
Oil must be clean, clear, and low in viscosity (not wood oil) to ensure optimum optical 
conditions. Oil must be wiped off objective lens with lens or fine tissue paper at the end of 
each working day. Remove oil from slides with tissue paper before storing to reduce risk of 
artifact and fungus.
35
At 100X magnification, use side-to-side or up-and-down sweeps of smear, taking care not to 
scan the same area twice. Observe 100-150 fields or for 5 minutes before calling a smear 
negative for AFB. 
36
To systematically observe slide (side-to-side or up-and-down pattern), stage must operate 
in both axes. To correctly read slides, microscope needs to be clean of dust that might 
interfere with identification of bacilli or give erroneous positive results. Use of known positive 
and negative controls can assist in determining quality of microscope. After cleaning, cover 
microscope with vinyl or cotton cloth and store in secure place free from moisture and dust. 
Keep microscope and slides away from dust and dirt to increase life of microscope and reduce 
artifact. 
37
Microscope area should have appropriate lighting and seating. Comfortable seating aids the 
technician’s attention span. Microscope area free from distractions or vibrations allows for 
greater attention span of technician and more accurate observation of slide.
38-39
Use a positive control smear containing AFB and a negative control smear containing no AFB 
stained at least once a week, daily recommended. However, each new stain solution must be 
tested with a positive control and negative control smear before staining of patients’ smears.
40
National or International Proficiency Testing Programs provide clinical specimens or slides to 
be tested by other laboratories to determine the tested laboratory’s ability to give an accurate 
report. If a laboratory has established such a link, it indicates the potential for a high degree of 
proficiency for the laboratory personnel. Results of proficiency testing must be seen.
41
Laboratories preparing and observing >15 AFB smears per week or 65 AFB smears per month 
are better able to maintain proficiency in this process (7,8). However, each technician should 
not examine >25 smears per day. 
Part 3: Laboratory Explanation Worksheet
13
Item  
No. Explanation
42
A reporting scheme of AFB found must be used. One scheme:
0 AFB/100 fields: negative•	
1-9 AFB/100 fields: actual number of AFB seen on whole slide •	
10-99 AFB/100 fields: 1+•	
1-10 AFB/field in 50 fields: 2+•	
>10 AFB/field in 20 fields: 3+ •	
With revised WHO case definition (6), the presence of at least one acid fast bacilli (AFB+) in 
at least one sputum sample is a sputum smear-positive pulmonary TB case.
43
For good quality assurance, a sample of previously examined slides should be rechecked 
in a blinded fashion. In addition, recheck positive slides for confirmation should be done. 
See External Quality Assessment for AFB Smear Microscopy (http://wwwn.cdc.gov/dls/ila/
documents/eqa_afb.pdf).
44 For good responsiveness to the needs of physicians and patients (and to minimize exposure), test results should be available within 24 hours of specimen receipt.
Safety Measures
45 Centrifuging can create infectious aerosols. Do not centrifuge unless appropriate safety precautions are in place.
46
If centrifugation takes place, centrifuge must have an internal cover plus cover for chamber. 
Dilute specimen with equal volume of 5% Na hypochlorite, place in container with leak-proof 
cover, and label with patient name or number. Centrifuge at >3000Xg (RCF). Sediment from 
specimens processed for isolation by culture may be used. Centrifugation slows turnaround 
time for clinician receiving results and not always worthwhile.
47
Although a Biological Safety Cabinet (BSC) is not required, it is recommended. Simple-to-
make cabinets requiring low-level sophistication and materials can be made but proof of their 
functionality needs assessing.
48 To minimize risk for exposure, ensure good ventilation—wind or fan is blowing over the shoulder and not in direction of others in the area.
49 Good laboratory practices (GLP) is to have hand washing station and to wash hands frequently with soap and water before and after every procedure. 
50
Dispose of contaminated material (especially used sputum cups, applicators, and slides) in 
accordance with standard biosafety procedures; this includes burning (incineration), burying, 
or autoclaving.
51
GLP includes cleaning of benches and equipment. Use phenolic agents or bleach solution for 
disinfectant for spills and before and after making smears (bleach solution is good for blood 
but less effective than phenolic agents against TB). To ensure greater ease with cleaning the 
benches and reduce risk of trapping infectious materials, it should be a continuous surface. 
52 To minimize risk for exposure, access to laboratory should be restricted and the door closed at all times.
53 Flammables (alcohols and organic solvents), strong acids, and strong bases should be stored in a flammables storage cabinet to minimize risk of spills that may cause fires or injuries.
Part 3: Laboratory Explanation Worksheet
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Item  
No. Explanation
54-55
For a well-functioning laboratory, standard operating procedures (SOP) for procedures used 
must be written, used, and readily available. Examples can be found on the Internet  
(Available at: http://www.epa.gov/quality/qs-docs/g6-final.pdf or http://www.fao.org/docrep/
W7295E/w7295e04.htm)
56 For a well-functioning laboratory, reduce risk of exposure to infectious materials. 
57-58 For a well-functioning laboratory, ensure that professionals staff the lab and that they maintain professional growth.
59
For well functioning laboratory, assess potential of TB disease (although exposure via other 
aspects of person’s life cannot be ruled out in many parts of the world). Aerosols containing 
Mycobacterium tuberculosis may be produced when handling leaking specimens, opening 
sample containers, and preparing smears. Ensure that sputum collection occurs away from 
others.
Culture
60
Although WHO case definition does not require culture and drug sensitivity testing (DST), 
in this world of increasing drug resistance this ability should be sought out for patients who 
are being retreated. Many NTPs have the ability to provide DST, especially for cases with 
suspicion of drug resistance. 
Part 3: Laboratory Explanation Worksheet
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Component 2: Health Education Evaluation Tool
Why the health education component of tool?
Health education and the relationship between patients and provider are important aspects to 
ensure treatment success. Use this section to observe patient intake on a typical day of either 
initiating treatment, providing directly observed therapy (DOT), or refilling medication. Ideally 
include patients in the intensive phase, at the beginning the continuation phase, and at some other 
point in the continuation phase of treatment. 
This tool should be used in combination with the clinical encounter evaluation tool, as items are 
not repeated between the two. 
Who should do this evaluation?
The evaluator should have a working knowledge of TB and either speak the language or use an 
independent translator to not disrupt the clinic. 
Further explanation of tool
There are 3 parts: 
Evaluation worksheet for evaluator to complete1. 
Scoring guide that provide suggested scores, rating, and comments and 2. 
recommendations section
Explanation worksheet that explains the importance of each item scored, including 3. 
references
In completing the evaluation worksheet, the evaluators should watch three to five patients coming 
for various stages of treatment. The point values are assigned from the experience gained during 
the pilot testing and are only suggestions. If you, as the evaluator, believe the scoring should 
be different that is appropriate, your experience along with the tool should direct your scoring. 
Resulting scores (suggested or locally adapted) of sub-sections of this component would be 
important to share with the program because the component covers a broad range of topics and 
different sub-sections may have different levels of competencies. In addition, you may want to 
give partial points. Partial item point values should be explained and recommendations given in 
the Comments and Recommendations section after the score guide. If major deficiencies are 
observed in any sub-section during the evaluation, the evaluator should intervene to improve the 
program where needed.
16
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Item 
No.
Point 
Value Description (Evaluator observes healthcare workers (HCW).
Suggested 
Score
Individual Patient Education
Adherence
1 5 Asks patients if they missed any days of therapy
2 3
If they missed treatment, asks what they did (whether took the next day) 
and counsel them about strategies for better treatment adherence (If no 
adherence problems, give 3 points)
3 5 Reminds patients about the dangers of defaulting from treatment 
4 1
If starting continuation phase, tell patients the difference between the 
intensive and now continuation phases of treatment (If not applicable, 
put N/A under score)
5 3
Congratulate patients on how far they have come in their treatment, tell 
them how much longer they have, and how important it is not to default 
now even though they feel well
Side Effects
6 5 Asks patients about any new symptoms (possible side effects to the medications) 
7 4 Reminds patients to come to the clinic immediately if they have severe side effects, such as cola colored urine
8 2 Asks female patients about pregnancy, if on streptomycin (If male or if not pregnant, give 2 points) 
9 2 Asks about eyesight and inability to see red and green colors, if on ethambutol (If ethambutol not given, give 2 points)
10 2 Offers patients ibuprofen (or other anti-inflammatory drug), if experiencing joint pains
11 2 Gives patient pyridoxine/vitamin B6, if experiencing tingling or burning sensation in hands or feet
Contacts
12 5 Tells patients to bring their children <5 years of age for testing
13 5 Tells patients to bring neighbors, family members, or other contacts who have been coughing for 2-3 weeks to the clinic for testing
Risks
14 4
Tells patients about risks to their liver of drinking alcohol and taking 
acetaminophen/paracetamol while on TB medications (Give 2 points for 
each)
15 1 Tells patients about risks to their lungs of smoking
16 3
Offers patients HIV testing, if not accepted before (If already accepted, 
give 3 points) (If testing not offered in TB clinic or location where offered 
not explained to patient, give 0 points)
Part 1: Health Education Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
Write point score in last column if item passed. Write “0” if item failed. Write N/A if “not 
applicable” or N/E if “not evaluated.”
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Item 
No.
Point 
Value Description (Evaluator observes healthcare workers (HCW).
Suggested 
Score
Follow-up:
17 2 Addresses all patient fears, misunderstandings, and questions
18 5
Makes next appointment for patients and tell them exactly where they 
need to return, including for sputum smears (If all explained except 
location of lab, give 4 points)
19 1 Invites any further patient questions and answer them accordingly
Community Education: (Workers or TB control programs)
Health Outreach Program:
20 2
Disseminates messages broadly using a variety of media, including 
religious, social, and economic organizations (This can only be assessed 
by making observations within the community and talking to community 
leaders. Give 1 point for some health outreach, but not a variety of 
outreach)
21 2 Uses cured patients as teaching resources
22 1 Holds group sessions as well as individual sessions
A
Score Achieved 
(add score achieved for items 1-22)
B Value of All  N/A OR N/E Responses
C
Suggested Total Score Possible
(65 points possible minus value in line B, above)
Part 1: Health Education Evaluation Worksheet
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Suggested Score Guide
Total Score from previous page (Line A)
Total Score Possible from previous page (Line C)
Rating 
If Line C=65, use RANGE below; if TOTAL POSSIBLE POINTS <65, use PERCENTAGE
Percentage 
Line A divided by 
Line C (A/C)*100
Range 
Use if Line 
C=65
Rating Suggested Time Until Next Assessment
>=85% 55-65 Excellent Needs assessment in 12-18 months
70-84% 46-54 Good Needs assessment in 9-11 months
50-69% 33-45 Poor Needs assessment in 6-8 months
<=49% <=32 Failed Needs assessment in 2-5 months
Comments and Recommendations (give item no.)
Part 2: Health Education Scoring Guide
Site     Country     Date
                 dd/mm/yy
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Part 3: Health Education Explanation Worksheet
Item  
No. Explanation
Individual Patient Education
Adherence
1-3
If patients stop drugs before treatment course is complete (even for a short time) the bacteria 
that are not killed can grow stronger than the drugs being taken. The patient’s TB bacteria can 
be stronger than the first-line treatment; the person can develop drug-resistant TB, so more 
drugs will be needed for cure. If a patient stops completely, he or she will become sick again; 
could spread TB to others, especially family members and young children; or could even 
die. Education should also include that for each day of therapy missed, additional days of 
treatment may be given, especially for HIV-infected patients. 
There are several ways that health staff can help patients predict potential problems and 
proactively solve them for successful, uninterrupted treatment. Simple daily life events and 
circumstances can be responsible for a patient not respecting his or her treatment regimen. 
The staff talk about these obstacles and help the patient find solutions.  
Link a daily routine to taking medicines to reduce the possibility of forgetting to take the •	
medicine. 
Possible routine activities could be a meal, before or after morning prayers, or bathing. •	
Potential activities will be different according to each population. 
If a dose is forgotten, it should be taken as soon as possible. If it is almost time for the •	
next dose, skip the missed dose and go back to the daily routine. 
The most important thing the staff can do is to help the patient see the causes of adherence 
problems, 
Define what the problem is with the patients, 1. 
Search for solutions together, and 2. 
Anticipate future problems. 3. 
It is important at each monthly visit that health staff revisit the adherence problems the patient 
has faced to make sure that they do not continue to be problems. One way to assess for 
missed pills is to have patient return each visit with pill bottle or blister pack (ideally, treatment 
should be provided under directly observed therapy).
4-5 Continuation versus intensive therapy should be explained even though the number of pills may be the same with combination pills.
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Item  
No. Explanation
Side Effects
6-11
Staff explain and ask about severe side effects. Most people have no problems with treatment. 
Most side effects will occur only in the beginning of treatment and go away on their own after 
a few weeks. Tell the patient to report any side effects, except orange/red urine when taking 
rifampicin, to the clinic. The most common side effects are stomach-gut complaints, such as 
loss of appetite, stomach pain, nausea, or vomiting. If the patient is nauseated after taking 
drugs, he or she should take medication with food or milk. Eating multiple small meals and 
eating before going to sleep may help with these symptoms. Because most of the drugs are 
broken down by the liver, swelling or damage of the liver can occur. However, severe liver 
damage (called severe hepatotoxicity) occurs in only 1 in 1,000 people. Liver swelling or 
damage cause nausea and vomiting and the urine to turn dark (like the color of cola). This 
must not be confused with urine turning orange/red, which happens when taking rifampicin. 
Tell the patient if he or she feels nauseated and has dark-colored (not red/orange) urine to 
stop taking the drugs and return to clinic immediately. A monthly color vision examination to 
assess ethambutol toxicity should be part of the routine screening examination.
Other side effects include (see Appendix A) (9):
Skin reactions such as itching or skin rash•	
Reactions of the nerves such as burning (with isoniazid)•	
Pains in the joints (with pyrazinamide)•	
Dizziness•	
Decrease in sight or difficulty telling red and green colors apart (with ethambutol)•	
Deafness (with streptomycin)•	
Contacts
12-13
Methods for contact tracing of close contacts can be found in the references (10). Anyone 
can get TB. If one person has TB and coughs, sneezes, or even talks or sings near another, 
that person can breathe in the TB bacteria and get TB. This is especially true for any children 
younger than 5 years old and for people with weak defenses, such as people with HIV 
infection. The biggest chance of getting TB is from spending a lot of time with people who 
have TB and who are not being treated, especially where there is poor air flow or in poorly 
ventilated areas. A lot of time usually means 8 hours or more. Any young children and others 
close to the TB patient who has symptoms of TB (night sweats, fever, a cough lasting more 
than 2-3 weeks, weight loss, fatigue, chest pain while breathing or coughing) should report 
to the clinic immediately to be tested for TB. Young children may have no symptoms, except 
failure to gain weight or weight loss.
Part 3: Health Education Explanation Worksheet
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Item  
No. Explanation
Risks
14-15
Health staff needs to explain risks and contraindications. Some patients receiving TB 
treatment also may be abusing alcohol or local brew at the time of their diagnosis and 
treatment. It is important that these patients are counseled on the risks that alcohol and local 
brew pose to those taking TB therapy. Specifically, the combination can have bad effects 
on the liver and nerves. There is the potential that TB treatment could harm the liver. Liver 
damage is more likely and more serious in people who are heavy alcohol users. 
Health workers should be open and honest with patients when talking about alcohol use and 
should be careful not to be judgmental.
In addition explain, 
Paracetamol or acetaminophen, like alcohol, is broken down by the liver. So paracetamol •	
can harm the liver. For headaches, joint or muscle pain, or fevers, inform patients that 
they can take drugs, such as ibuprofen or aspirin. Children should not take aspirin, if they 
have a fever. 
Cigarette smoking can scar the lungs and prevent the lungs from clearing the sputum or •	
phlegm. TB patients should stop smoking or never start. 
16
Staff needs to recommend HIV testing. HIV affects the body’s defenses or immune system 
and makes people more vulnerable to TB; TB can develop more often, rapidly, and more 
often travel outside the lungs to other parts of the body, like the lining of the brain, causing TB 
meningitis. Having TB does not mean the patient has HIV. Both HIV and TB have treatment 
and TB can be cured. If close exposure to smear-positive patients occurs but the HIV-infected 
person is without disease, this person should receive prophylaxis (isoniazid 5 mg/kg or 300 
mg daily) for 6 months (1, 11, 12).
Follow-up
17-19 Staff needs to be open by addressing fears, welcoming questions, making next appointment. 
Community Education
Health Outreach
20
Broadly disseminate messages using a variety of mediums to maximize the number of people 
with TB knowledge and their ability to communicate these messages to others. By saturating 
the community with knowledge, healthy behaviors regarding prevention, early case detection, 
and decreasing stigma become social norms. 
Religious services can be one of the best ways to disseminate messages. Religious leaders 
are often well respected for their views even in nonreligious matters, such as health. They 
also have a captive audience at religious services, which can be used creatively to talk about 
disease in the community. 
Social organizations, such as women’s groups, youth groups, etc. often can creatively adapt 
messages to local situations and often have capable and willing participants. 
Economic organizations, such as farmer’s cooperatives or local business owners can 
also be important allies to get messages into the community. In low-resource settings, these 
organizations are often composed of men, who are responsible for decision-making in their 
households. Thus, getting their cooperation and understanding can affect entire households.
Other media not mentioned here also should receive partial points. 
21
Use cured patients as teaching resources because of their knowledge of the disease, 
treatment regimens, drug side-effects, etc. Do not identify any individuals currently with 
TB. They can also be helpful in decreasing the stigma associated with the disease by 
demonstrating that TB is curable.
22 Use group sessions as well as individual sessions to reach as many people in as many ways as possible.
Part 3: Health Education Explanation Worksheet
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Component 3: Clinical Encounter Evaluation Tool
Why the clinical encounter component of tool?
The relationship between patients and provider and health education are important aspects to 
ensure treatment success. The tool should be used in combination with the health education tool, 
as items are not repeated between the two. 
Who should do this evaluation?
The evaluator should be a TB clinician or expert with knowledge of the clinical-care side of TB 
treatment. As always, guidelines from the National TB Program (NTP) in the host country and 
the refugees’ country of origin should be followed and used as a reference. Other references are 
provided (11-13). 
Further explanation of tool
There are 3 parts: 
Evaluation worksheet for evaluator to complete1. 
Scoring guide that provide suggested scores, rating, and comments and 2. 
recommendations section
Explanation worksheet that explains importance of each item scored, including 3. 
references
Evaluators should watch three to five patients coming for various stages of treatment (intensive 
and continuation phase). The point values are assigned from the experience gained during the 
pilot testing and are only suggestions. If you, as the evaluator, believe the scoring should be 
different, that is appropriate, your experience along with the tool should direct your scoring. 
Resulting scores (suggested or locally adapted) of sub-sections of this component would be 
important to share with the program because the component covers a broad range of topics and 
different sub-sections may have different levels of competencies. In addition, you may want to 
give partial points. Partial item point values should be explained and recommendations given in 
the Comments and Recommendations section after the score guide. If major deficiencies are 
observed in any sub-section during the evaluation, the evaluator should intervene to improve the 
program where needed.
26
27
Item  
No.
Point 
Value Description
Score
Suggested
Case Ascertainment: Evaluator asks community health worker
1 3 Patients found by active surveillance—community healthcare workers or TB treatment supporters visit households looking for cases
Clinical Patient Evaluation: Evaluator observes healthcare workers 
(HCW)  
2 3
Gives (or gave at start of therapy) patients a simple explanation of what 
TB disease is and how it is contracted (if not observed, ask HCW what 
they would say. Do not ask as yes or no questions)
3 4
Asks (or asked at start of therapy) patients about disease symptoms 
and tell them the symptoms will go away as they start treatment (Give 2 
points each for asking about symptoms and explaining will go away)
4 0.25 Asks (or asked at start of therapy) about contact history
5 4 Asks and record (or asked and recorded at start of therapy) any prior TB treatment, specifies medications
6 0.5 Asks about allergies to other (non-tuberculosis) medications and records it (with the symptoms of allergic reaction if possible)
7 4
Obtains and record weight each month 
(Evaluator can obtain this information by examining 5 medical records of 
patients [preferably medical records of discharged patients]. If a weight 
is obtained monthly, give 4 points. If 4 weights are obtained in 6 months 
of treatment, give 3 point; if 3 weights are obtained, give 2 points; 
otherwise, give 0 points. 
OR evaluator can observe 4-5 patient encounters. If all patients with 
a weight obtained, give 4 points; If only 1 patient without a weight 
obtained, give 3 points; if 2 patients without a weight obtained, give 2 
points; otherwise, give 0 points, weights obtained must be reordered 0 
points)
8 0.25 Signs (or signed at start of therapy) charter with patient  (see Appendix B)
9 4 Asks patient about possible signs of drug resistance (After patients seen, ask HCW what are the signs. Do not ask as yes or no questions).
10 3 Provides supplemental feeding monthly (If only during intensive phase, give 2 points)
Clinic Infection Control: Evaluator Observes
11 2 Patient flow and comfort
12 3
Level of infection control in clinic—sunlight, ventilation, mask wearing (If 
only sunlight and ventilation, give 2.5 points; if only wearing mask but 
poor ventilation, give 0 points)
13 2
Necessary materials (gloves, disposal or reusable medical materials, 
disinfection) (NOTE: these materials do not prevent TB transmission, 
they are good medical practice) (If all materials are seen, give total 
points; if 2 materials are seen, give 1 point; if less than 2 materials are 
seen, give 0 points) 
Part 1: Clinical Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
Write point score in last column if item passed. Write “0” if item failed. Write N/A if “not 
applicable” or N/E if “not evaluated.”
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Item  
No.
Point 
Value Description
Score
Suggested
14 3 HCW administer streptomycin under antiseptic means (if multiuse vial, top is cleaned and sterile syringe used each time)
15 3 HCW dispose of needles safely
Medications 
For items 16-18: Ask the health workers (HCW) to explain the different phases of medication (do not 
ask as yes or no questions but ask for his/her explanation of phases)
16 4 HCW know intensive and continuation medications for first-time treatment per WHO or national guidelines (Give 2 points for each phase)
17 4 HCW know intensive and continuation medication for retreatment (Give 2 points for each phase)
18 3 HCW know to stop treatment for persistent smear-positive patients
19 1 Evaluator observes chart with maximum dosage for each medication (often found on wall of clinic, but may need to ask for it)
20 5
Program gives DOT (observed swallowing), for how long (√ the box)?
not given	q
2 months	q
total course 	q
(Give 5 points for total course, give 3 point for 2 months; if DOT not 
given, but bottles or blister packs asked for and examined at each 
subsequent visit, give 1 points)
21 4
For DOT, by whom (√ the box)?
medical/clinical officer/auxiliary worker 	q
community health worker	q
family member 	q
(Give 3 point for non-family member)
22 1 Evaluator observes chart with side effects (often found on wall of clinic, but may need to ask for it)
Laboratory Follow-up
For items 23-24: Ask the health workers (HCW) to explain sputum smear intervals (do not ask as 
yes or no questions but ask for their explanation). In addition for item 23, review the individual patient 
records or the medical records of those presenting for the day
23 4
HCW requests sputum smears at intervals according to Ministry of 
Health or World Health Organization for initial smear-positive case (If 
less than 3 times, give 2 points; if less than 2 times, give 0 points)
24 3 HCW repeats sputum smears in 1 month for patients with positive smear 
25 2
Evaluator observes HIV testing methods for reliability (cold chain, kits 
within expiration date—full assessment under HIV program) 
(Give 1 point, if kits within expiration date and 1 point, if good chain 
equipment used [refrigerator in correct range for kits]. NOTE: kits should 
be those that can be stored at 30°C; however, many areas where 
refugees reside and resource-limited areas can have average daily 
temperatures >35°C). 
Part 1: Clinical Evaluation Worksheet
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Item  
No.
Point 
Value Description
Score
Suggested
Contact Tracing and Prophylaxis: Evaluator observes HCW  
For items 26-27: Ask the health workers (HCW) to explain prophylaxis and protection of BCG (do not 
ask as yes or no questions but ask for his/her explanation).
26 3
Gives prophylaxis to children less than 5 years old and to HIV-infected 
persons with exposure to smear-positive case (Give 2 points, if give 
prophylaxis only to HIV-infected persons)
27 3 Can describe protection and lack of protection of BCG (1 point)  Give BCG to unvaccinated children less than 5 years old (2 points)
Policies: Clinic staff
28 4 Has documented plans and activities for non-adherence (default treatment)
29 2
Has mechanism (referral sheet for transfer in and transfer our) and 
follow-up activities for transfers (If referral sheet but no follow-up 
activities back from referral facility, give 1 points)
30 4.5 Has access to radiology services for cases where smears are negative, but question of TB still remains
Hospital: Staff
31 3 Has established criteria for hospitalization (If only verbal criteria that are well explained, but not written, give 2 points)
32 3 Has infection control in hospital—sunlight, ventilation, mask wearing (If only sunlight and ventilation, give 2.5 points)
33 0.5 Provides sputum pots/mugs with covers and disinfectant to hospitalized patients
34 3
Has adequate waste management (incinerator; burial not desirable for 
hospital capacity; may be the same the laboratory uses) (If burial, give 1 
point)
A
Score Achieved
(add score achieved for items 1-34)
B Subtract Number of N/A OR N/E Responses
C
Suggested Total Score Possible 
(96 points possible minus value in line B, above)
Part 1: Clinical Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
Write point score in last column if item passed. Write “0” if item failed. Write N/A if “not 
applicable” or N/E if “not evaluated.”
30
 
Suggested Score Guide
Total Score from previous page (Line A)
Total Score Possible from previous page (Line C)
Rating 
If Line C=96, use RANGE below; if TOTAL POSSIBLE POINTS <96, use PERCENTAGE
Percentage 
Line A divided 
by Line C 
(A/C)*100
Range 
Use if Line 
C=96
Rating Suggested Time Until Next Assessment
>=85% 82-96 Excellent Needs assessment in 12-18 months
70-84% 67-81 Good Needs assessment in 9-11 months
50-69% 48-66 Poor Needs assessment in 6-8 months
<=49% <=47 Failed Needs assessment in 2-5 months
Comments and Recommendations (give item no.)
Part 2: Clinical Scoring Guide
Site     Country     Date
                 dd/mm/yy
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Item 
No. Explanation 
Case Ascertainment
1 Passive detection is waiting for patients to present to clinic with symptoms; given the chronic 
nature of much TB, this underestimates prevalence of the disease. Active detection is having 
healthcare workers, volunteer or paid, community health workers or TB treatment supporters 
(available at: http://whqlibdoc.who.int/hq/2003/WHO_CDS_TB_2003.312.pdf) actively go into 
the community to look for cases.
Clinical Patient Evaluation 
2-6 Observe at least one first-time assessment of a patient, among the 3-5 patients, with potential 
TB (in an environment with minimal risk of exposure, e.g., outside) to determine if all items 
are being asked (these items may only be asked the first-time). If a new patient encounter 
is not observed, ask the healthcare providers after all patients are seen what they asks new 
patients (you may want to pretend to be the patient to make this less artificial). Asking about 
history of contact with TB, unless a child; allergies to other medications is not as important as 
asking about prior TB treatment. Prior treatment increases a person’s risk of having drug-
resistant TB.
7 View at least five arbitrarily selected medical records to determine whether weights are 
obtained and recorded monthly. In some settings, weekly (during intensive phase) or monthly 
(during continuation phase) weights may be the only objective sign of improvement on 
treatment.
8 Having patients sign a charter places greater responsibility of care on the individual and is a 
good but not required procedure (see Appendix B) (14).
9 Continued cough and other symptoms, no weight gain, and continued smear-positive sputum 
might imply drug-resistant TB. Also, close contacts of a patient with drug-resistant TB have a 
greater risk of acquiring drug resistant TB themselves. The healthcare workers need to ask 
patients about these symptoms.
10 Most programs/organizations support supplemental feeding of HIV patients; such should be 
done for TB patients as well.
Clinic Infection Control 
11-13 Ensure patients are not sitting in a confined area for periods of time; although gloves and 
masks are not required, appropriate disposal and disinfection of medical material is required. 
Gloves and coats or gowns do not prevent TB transmission, but they are good medical 
practice.
14 Nosocomial (hospital-acquired) infections can occur as a result of poor technique during 
injection procedures.
15 Needlestick injuries of healthcare workers increase their risk for bloodborne infections. Never 
recap needles. Dispose of them in a puncture-proof container. If standard ‘sharps container’ is 
not available, a container of thick plastic, metal, or wood can be used.
Medications 
16-18 Use World Health Organization (WHO) or National TB Program (NTP) regimen.
19 Observe chart with dosage by weight and presence of scale.
20-21 The workers doing DOT should be trained in the importance of DOT. The workers need to see 
the person swallowing the pills. This should occur at least during the intensive phase. DOT can 
be given daily (except Sunday) or if rifampicin given, three times per week.
22 The most common side effect is stomach-gut complaints such as loss of appetite, stomach 
pain, nausea, and vomiting. Effects on the liver cause nausea, vomiting, and a change of urine 
to dark color (like the color of cola). These effects can occur with first-line drugs. Paresthesia 
can occur with isoniazid and arthralgia with pyrazinamide. A chart with this information must be 
observed.
Part 3: Clinical Evaluation Explanation
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Item 
No. Explanation 
Laboratory Follow-up 
23-24 Sputum smears are obtained according to schedule of WHO or NTP guidelines and before 
starting the continuation phase.
25 All TB patients are offered HIV counseling and testing, but only if testing is known to be 
reliable—cold chain guaranteed and documented.
Contact Tracing 
26-27 Family members, especially children and those infected with HIV, have the greatest risk of 
becoming infected and developing TB and need to be followed clinically on a regular basis. 
If exposed to smear-positive family members but without disease, HIV-infected persons and 
children less than 5 years should receive prophylaxis (isoniazid 5 mg/kg or 300 mg daily) for at 
least 6 months. As shown in some studies, BCG does not prevent pulmonary TB, but it does 
reduce the risk for disseminated or extrapulmonary TB, especially in children <5 years old (15-
17). Live vaccines should not be given to HIV-infected persons. If tuberculin skin test (TST) is 
available, children of smear-negative family members should be tested and given prophylaxis, 
if TST is10 mm or more (11, 12, 18). 
Policies
28-29 Set mechanism and timing for follow-up on defaulters, usually by 2 missed appointments. 
Community health workers or TB treatments supporters can be helpful with findings patients 
who have defaulted therapy. HCW should generate lists at least monthly (more often for 
patients in intensive phase). Set mechanism and activities for reintegration or repatriation, 
if communication established and healthcare available and reliable in country of origin 
(1).
30 Although chest radiograph is not a part of WHO case definition of TB, access to this service is helpful in difficult cases where the sputum smear is negative.
Hospital
31
Indications for hospitalization
Severe disease (e.g., meningitis, extreme wasting, blood in sputum) requiring •	
nursing care and close observation
Serious treatment complications (e.g., jaundice, severe skin reaction such as •	
Stevens Johnson syndrome)
Serious concomitant disease (e.g., malaria, diabetes, liver or kidney failure)•	
Logistical difficulty (e.g., patient from remote area).•	
32-34
Great risk of TB transmission exists in hospitals where patients are already 
immunocompromised to some degree. TB patients should be separated from other patients 
in a well-ventilated area. Each patient should have a covered container for sputum, which is 
disposed of safely (preferably incinerated or autoclaved). TB patients should be transported 
to other areas of the hospital as little as possible and should wear masks during transport. 
Administrative control (prompt recognition, separation and treatment of infectious patients) 
and environmental control (ventilation, UV light) measures are the first two lines of defense 
against nosocomial transmission of TB. Because TB is transmitted in the air, gloves and 
coats or gowns do not reduce the risk of TB transmission but handwashing and glove use 
are good hospital and laboratory practice. Quaternary ammonium compounds are ineffective 
for destroying M. tuberculosis; chlorine in high concentrations at a 1:5 dilution (250 ppm) for 
10 minutes (less concentration and time, not biocidal) and 5% phenol in water have biocidal 
activity (19). Use of personal protective equipment and good waste management are important 
in reducing infections to patients and staff. 
Part 3: Clinical Evaluation Explanation
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Component 4: Data Management and Logistics 
Tool
Why the data management component of the tool?
Systematic record keeping plays another crucial role to a well functioning TB program. Good 
record keeping is necessary for following and managing individual patients effectively, determining 
whether the program is performing according to accepted standards, and identifying problems that 
require corrective actions (1).
Who should do this evaluation?
The evaluator should be a clinician or TB expert with knowledge of the clinical and programmatic 
care side of TB treatment. As always, guidelines from the National TB Program (NTP) in the host 
country and the refugees’ country of origin should be followed and used as a reference. In addition, 
other references are provided (1, 20). 
Further explanation of tool
There are 3 parts: 
Evaluation worksheet for evaluator to complete1. 
Scoring guide that provide suggested scores, rating, and comments and 2. 
recommendations section
Explanation worksheet that explains the importance of each item scored, including 3. 
references
 The point values are assigned from the experience gained during the pilot testing and are only 
suggestions. If you, as the evaluator, believe the scoring should be different that is appropriate your 
experience along with the tool should direct your scoring. Resulting scores (suggested or locally 
adapted) of sub-sections of this component would be important to share with the program because 
the component covers a broad range of topics and different sub-sections may have different levels 
of competencies. In addition, you may want to give partial points. Partial item point values should 
be explained and recommendations given in the Comments and Recommendations section after 
the score guide. If major deficiencies are observed in any sub-section during the evaluation, the 
evaluator should intervene to improve the program where needed.
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Item 
No.
Point 
Value Description (explanations of these items are on the next sheet)
Score  
Suggested
Registers: Evaluator
1 42 Observes patient registry exists and is functional
Record Keeping for Diagnosis and Treatment: Evaluator observes
For items 2-6: Arbitrarily (not consecutive) select 10 TB medical records of the last 5 months for 
patients in continuation phase (If 9-10 medical records are correct for an item, give 4 points; if 7-8 
medical records correct, give 3 points; if 5-6 medical records correct, give 2 points; if less correct, give 
0 points) 
If medical records are not used, check appointment cards of 5 patients (If 5 appointment cards are 
correct for an item, give 4 points; if 4 appointment cards correct, give 3 points; if 3 appointment cards 
correct, give 2 points; if less correct, give 0 points) for:
2 4 Results of initial smear indicated
3 4 Smears examination at 2 months indicated
4 4 Additional smears indicated (at 5 months, at end of treatment)
5 4
Dates and regimen of intensive phase of treatment indicated (Give 2 
points for each [date and regimen] if written for each visit; give 1 point for 
each, if 1 missing; give 0 points, if  2 or more missing)
6 4
Dates and regimen of continuation phase of treatment indicated (Give 2 
points for each, if written for each visit; give 1 point for each, if 1 missing; 
give 0 points, if  2 or more missing)
Reports: Staff can provide evaluator
7 3 Monthly or quarterly (every 3 months) reports for number of patients 
8 3 Monthly or quarterly reports for patient types—pulmonary/extrapulmonary, smear-positive/smear-negative
9 4 Monthly or quarterly reports for patient outcomes—rates for cure, treatment completion, default, relapse, transfer, death 
10 3 Clinic gives numbers to the National TB Program on at least quarterly basis
11 3 Clinic gives numbers to HIS (Health Information System of United Nations Refugee Agency—put N/A, if not refugee setting) on a monthly basis
Default Tracing
12 4
Healthcare workers (HCW) uses 14 days after overdue appointments for 
tracing default patient in intensive phase (If tracing at 21- 30 days, give 2 
points; if tracing at 28-35 days, give 1 point)
13 4
HCW uses 2 months after overdue appointments for tracing default 
patient in continuation phase (If tracing at 3-4 months, give 2 points; if 
tracing at 4-5 months, give 1 point)
14 4 Clinic has default rate <10% (If 11%-15%, give 2 points; if >15%, give 0 points)
Part 1: Data Management Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
Write point score in last column if item passed. Write “0” if item failed. Write N/A if “not 
applicable” or N/E if “not evaluated.”
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Item 
No.
Point 
Value Description (explanations of these items are on the next sheet)
Score  
Suggested
Contact Tracing and Treatment: Clinic 
15 4 Has proportion of pediatric patients (<15 years old) to total patients >11% (If 5%-10%, give 3 points; if <5%, give 0 points)
Treatment, Medication, Supplies: Clinic
16 4 Has sufficient supply of anti-TB drugs to allow for 2 months beyond next shipment (If 1 month, give 3 points)
17 4 Maintains drugs in appropriate location (not too hot—this can be assured with thermometer monitoring temperature during the hottest time of day)
18 4 Drugs are from a reputable source, such as the National TB Program
19 4 Does not have expired drugs 
20 3 Has adequate supplies of needles, syringes, diluent for injection for 2 months beyond next shipment (If 1 month, give 2 points)
A
Score Achieved
(add score achieved for items 1-20)
B Subtract Number of N/A OR N/E Responses
C
Suggested Total Score Possible
(73 points possible minus value in line B, above)
Part 1: Data Management Evaluation Worksheet
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Part 2: Data Management Scoring Guide
Suggested Score Guide
Total Score from previous page (Line A)
Total Score Possible from previous page (Line C)
Rating 
If Line C=73, use RANGE below; if TOTAL POSSIBLE POINTS <73, use PERCENTAGE
Percentage 
Line A divided by 
Line C (A/C)*100
Range 
Use if Line 
C=75
Rating Suggested Time Until Next Assessment
>=85% 62-73 Excellent Needs assessment in 12-18 months
70-84% 51-61 Good Needs assessment in 9-11 months
50-69% 37-50 Poor Needs assessment in 6-8 months
<=49% <=36 Failed Needs assessment in 2-5 months
Comments and Recommendations (give item no.)
Site     Country     Date
                 dd/mm/yy
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Item 
No. Explanation 
Registers
1
Good record keeping is important for a well-functioning laboratory and clinic. Actual register 
books or logs should be provided by National TB Program (NTP). Observe registries and 
check for continual entries (no missing weeks or months that are not during holidays). Ensure 
that only one register each per lab, suspect TB, and TB patients is used at a time.
Record Keeping for Diagnosis and Treatment
2-6
Accurate record keeping is a key requirement for good program performance. Use NTP or 
WHO guidelines for frequency of sputum examinations. A common frequency is to have 
sputum examination results recorded at the start of intensive therapy; after 2-3 months of 
therapy (at completion of intensive therapy); after 5 months of therapy; and at completion (6 
or 8 months) of therapy. Use WHO (13) or NTP first-time and retreatment regimens.
Reports
7-10
Regular analysis and reporting of cases is a key requirement for good program performance. 
Observe either monthly or quarterly (every 3 months: January-March, April-June, July-
September, October-December) tallies and reporting system. Reporting aggregated data to 
NTP is important for good program management. This should occur on at least a quarterly 
basis. 
Reported analyses include (1): 
Number of suspect cases (lab registry)=A•	
Number of sputum samples examined (lab registry)=B •	
Number of positive sputum smears (lab registry)=C•	
Number of smear-positive patients=D •	
Percent positive smears•	  [(C divided by B)*100] 
Percent of smear-positive patients•	  [(D divided by A)*100] 
Cure rate•	 =Number of patients smear-negative in last month of treatment divided 
by those with newly diagnosed smear-positive TB (>85% is global cure rate target) 
or divided by those alive at end of treatment (survivors) in same period of time. 
Default rate•	 =Number of patients whose treatment was interrupted for >2 
consecutive months divided by the number with newly diagnosed smear-positive 
TB in same period of time. 
Relapse rate•	 =Number of patients who were previously treated and cured or 
completed treatment and now smear-positive divided by the number with newly 
diagnosed smear-positive TB in same period of time. 
Transfer rate•	 =Number of patients who were transferred to another TB program 
to continue treatment divided by the number with newly diagnosed smear-positive 
TB in same period of time.
Death rate•	 =Number of patients who died from any cause during treatment divided 
by those with newly diagnosed smear-positive TB (>85% is global cure rate target) 
or divided by those alive at end of treatment (survivors) in same period of time.
11
United Nations Refugee Agency (UNHCR) Health Information System (HIS) should be used 
as the reporting system for refugee camps. HIS has the ability to generate Ministry of Health 
reports.
Part 3: Data Management Explanation Worksheet
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Item 
No. Explanation 
Default Tracing
12-14
Aggressive education about adherence throughout treatment process and home visits to trace 
nonadherent patients as soon as they interrupt their treatment (at time of second missed visit) 
is paramount to successful TB control program. Use outreach workers, such as TB treatment 
supporters to achieve this. Default rate is an excellent indicator of how well your program is 
doing. This rate should be analyzed on a quarterly basis and should remain <10%.
Contact Tracing
15
High rates of childhood TB (less than 5 years of age) compared with total cases imply good 
rates of contact tracing and case ascertainment for a program. Over 40% (33%-50%) of 
household contacts can be infected (5), with children having a greater risk of progressing to 
disease. 
Treatment, Medication, Supplies
16-17
For good program performance, guarantee the supply and quality of medications. Days of 
drugs out of stock can increase risks for developing drug-resistant TB. Because tropical 
countries with hot climates have a high rate of TB disease, maintaining drugs and not using 
expired drugs is paramount. 
18-19
In addition to stock-outs, drugs that are expired or not tested for efficacy can lead to drug 
resistance. Drugs must always be procured from a reputable institution, such as the NTP. 
Quality assurance of the medications needs to be a part of the determination of their efficacy. 
20 For good program performance, guarantee the stock of supplies. 
Part 3: Data Management Explanation Worksheet
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Online Resources
Centers for Disease Control and Prevention
Educational material and training
TB Elimination: •	 http://www.findtbresources.org/scripts/index.cfm?FuseAction=OrderMatl
http://www.cdc.gov/tb/pubs/default.ht•	 m 
Fact sheets 
Exposure to TB •	
TB and HIV/AIDS •	
TB Can Be Treated •	
Testing for TB •	
You Can Prevent TB•	
Posters: http://www.cdc.gov/tb/pubs/Posters/default.htm
Mantoux tuberculosis skin test poster •	
Stop TB fact sheet•	
Interview techniques
Effective TB Interviewing for Contact Investigation: Self-Study Modules (available at: •	 http://
www.cdc.gov/tb/pubs/Interviewing/selfstudy/ default.htm)
World Health Organization
http://www.who.int/tb/en/
TB epidemiology and surveillance workshop, all templates: •	 http://www.who.int/tb/
surveillanceworkshop/all_templates/default.htm 
TB community supporter materials: •	 http://whqlibdoc.who.int/hq/2003/WHO_CDS_
TB_2003.312.pdf
A guide for tuberculosis treatment supporters, 2002:  •	 http://whqlibdoc.who.int/hq/2002/
WHO_CDS_TB_2002.300.pdf
Community TB care in Africa project: •	 http://www.who.int/tb/people_and_communities/
commcare/background/en/index1.html
Revised TB recording and reporting forms and registers - version 2006:  •	
http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.373_eng.pdf 
A guide to monitoring and evaluation for collaborative TB/HIV activities, 2009: •	
http://whqlibdoc.who.int/publications/2009/9789241598194_eng.pdf
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Other Organizations
International Union Against TB and Lung Disease: •	 http://www.iuatld.org/index_en.phtml
Partners in Health Community TB Treatment Supporter Training Guide: •	 http://model.pih.org/
accompagnateurs_curriculum 
Francis J. Curry National Center International Resources: •	 http://www.nationaltbcenter.edu/
international/index.cfm 
Stop TB Resource Center: http://www.stoptb.org/resource_center/documents.asp•	
Laboratory Resources
International Laboratory Standards/Guidelines: http://wwwn.cdc.gov/dls/ila/TB_Toolbox.aspx 
External Quality Control for AFB Smear Microscopy: http://wwwn.cdc.gov/dls/ila/documents/
eqa_afb.pdf 
AFB Smear Staining (poster): http://wwwn.cdc.gov/dls/ila/documents/AFBSmearStaining.pdf 
Quality Issues of AFB Smear Preparation and Staining Technique (poster): http://wwwn.cdc.gov/
dls/ila/documents/qi.pdf 
African and Asian Resources
Kenya specific TB communication strategy information—Lights of Hope: A National 
Communication Strategy for Fighting Tuberculosis in Kenya: http://www.path.org/publications/
details.php?i=1399
Treatment supporters and patient booklets for Tanzania and Namibia (developed by the Norwegian 
organization LHL): http://www.lhl.no/portal/page?_pageid=513,189797&_dad=portal&_schema=
PORTAL&articleId=38836&artSectionId=1875 
Low-literacy patient educational materials developed for South Africa: http://www.booksofhope.
com/ 
TB: a clinical manual for South East Asia: http://www.popline.org/docs/1631/288834.html 
Promoting cultural sensitivity: an ethnographic guide for tuberculosis programs providing services 
to Hmong persons from Laos: http://www.cdc.gov/tb/EthnographicGuides/Hmong/default.htm
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Appendix A: Supplemental Health Education 
Materials
Sputum Collection
Health education poster that staff can put on walls in lab or clinic to remind themselves, and make 
patients aware, of proper method for collecting sputum. Available in PDF form for printing on 
the tool’s companion CD-ROM. The evaluator may want to print some out before traveling to TB 
control program for distribution to augment existing educational materials. 
Mild Side Effects and Their Management
Health education poster that the staff can put on walls of TB control program to remind themselves 
and make patients aware of mild side effects of therapy. Available in PDF form for printing on 
the tool’s companion CD-ROM. The evaluator may want to print some out before traveling to TB 
control program for distribution to augment existing educational materials. 
TB Admissions Talk
Health education posters that the staff can use to remind themselves what to tell the patients. 
Available in PDF form for printing on the tool’s companion CD-ROM. The evaluator may want 
to print some out before traveling to TB control program for distribution to augment existing 
educational materials.
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Patient Must Know:
Importance of giving  y
sputum rather than saliva
Visual difference between   y
sputum and saliva
Importance of not  y
being near others when 
producing sputum
Patient Must:
Rinse mouth with water   y
(provide cup and water)
Open container but keep cap   y
and inside clean
Take three to four (3-4)  y
deep breaths
Hold breath for 3-5 seconds   y
after each deep breath 
Give deep cough with last   y
breath to bring up sputum 
from lungs
Put sputum, not saliva, into   y
container
Provide enough (3-5 mL)  y
sputum  
Sputum Collection
From the Monitoring and Evaluation Tool for Tuberculosis Programs in Refugee and Post-Conflict Settings
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Drug Side Effect Management
Rifampicin
No appetite, 
nausea, stomach 
pain
Eat small meals and 
before bedtime
Rash Take antihistamines, if worsens see health officer
Orange/Red 
Urine
Reassure patient—an  
expected effect of drug
Pyrazinamide 
(PZA)
Joint pain Take ibuprofen or aspirin  (if not a child)
No appetite, 
nausea, stomach 
pain
Eat small meals and  
before bedtime
Rash Take antihistamines, if  worsens see health officer
Isoniazid 
(INH)
Burning/tingling 
in hands/feet
Take vitamin B6/
Pyridoxine 100mg
No appetite, 
nausea, stomach 
pain
Eat small meals and before 
bedtime
Rash Take antihistamines, if  worsens see health officer
Ethambutol Eye problems Stop medicaton and see  health officer immediately
Mild Side Effects of TB Drugs  
and Their Management
From the Monitoring and Evaluation Tool for Tuberculosis Programs in Refugee and Post-Conflict Settings
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TB ADMISSION TALK
PATIENTS MUST KNOW:
TB can be cured  y and disease symptoms go away 
with treatment
TB can be easily spread; y  learn how to stop the 
spread  
Always cover your mouth when coughing or  y
sneezing  
If you default (stop taking your drugs) your family  y
could get TB; and you could possibly die
If a dose is missed, take it as soon as you  y
remember but not within 8 hours of the next dose
DOT (Directly Observed Therapy) works y  when it 
lasts for at least 2 months
Be patient: TB drugs take a while to work; y  learn 
about the two different phases 
If pregnant, tell your doctor,  y you should not take 
streptomycin injections
Bring in children y  less than 5 years old to be 
examined, because of high risks of TB 
Bring in contacts,  y neighbors, family members, or 
other who are coughing for 2-3 weeks to be tested 
for TB
Vaccinate children  y less than 5 years of age with 
BCG to prevent severe forms of TB
Report side effects and if they are severe come to  y
the clinic immediately
Take no alcohol y  while on treatment because of liver 
damage 
Take no Paracetamol y  while on treatment because 
of possible liver damage
G y et HIV testing, there is treatment 
TB Admission Talk
Patients Must Know:
From the Monitoring and Evaluation Tool for Tuberculosis Programs in Refugee and Post-Conflict Settings
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Appendix B: TB Patient Rights and Duties 
By signing this charter, you are promised the following about your tuberculosis (TB) care while in 
this clinic (the healthcare worker will tick each item as it is discussed with you):
Care
You will not be asked to pay for your sputum tests, your medical exams, or your TB treatments.  q
All services are free.
You will receive advice from clinic staff about your treatment and your health. q
Respect
You will be treated with respect when you come to this clinic. You will not be treated any  q
differently because of your gender, religion, culture, your health status, ethnicity, or nationality.
Your medical information will be shared with healthcare workers only. q
Information
You will get information about your health and risks to your children, family, friends, neighbors,  q
and others so you can help protect them.
You will be told about your treatment program and common risks to medicines and how to  q
manage them.
You will and avoid know the names of your medications, how much of each you will take, and  q
how they work.
Your TB card is yours to keep as a record of your treatment and will be filled out each time you  q
come to the clinic to show you your progress.
Support
You have the right to complain if you have any problem with your treatment.  q
You have the right to seek support and advice and share experiences. You may do so at the  q
tuberculosis clinic or other areas.
By signing this charter, you agree to the following (the healthcare worker will tick each item as it is 
discussed with you): 
Treatment
You will take your medication exactly as it is explained to you. You will take it every day for the  q
entire time (6-8 months).
You will tell us if you have any problems with your medicine, if you start feeling sick, if you miss  q
any days of medicine, or if you stop taking your medicine for any reason.
Information
You will tell us about your health—both in the past and now, including past illnesses,  q
treatments, and side effects so that we can best help you.
You will tell us about people you are close to, including your children, family, friends, and  q
neighbors so we can see if they have TB disease.
Family and Community Health
You will tell us if any of your family, neighbors, or community show signs of TB disease. q
You will tell others to come to the clinic if you think they have TB disease. q
Respect
You will respect other TB patients, their privacy, and their dignity. q
Patient Name: Staff Name:
Patient Signature: Staff Signature:
Date: Date:
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Appendix C: Program Implementation
Program Implementation Evaluation Tool
Why the program implementation tool?
Use this section when the healthcare implementing partner is asked whether it is appropriate 
to start a TB control program in a resource-poor, post-conflict, or refugee setting. TB control is 
not considered a part of responding to the acute stage of a humanitarian emergency. However, 
TB among refugees and other migratory populations is an important public health problem and 
as conflicts become protracted and more camps become long-term settlements, the need for TB 
control programs increases.
Who should do this evaluation?
This tool should be used by program managers for stable camp settings.
Further explanation of tool
There are 3 parts: 
Evaluation worksheet for evaluator to complete1. 
Scoring guide that provide suggested scores and possible time for reevaluating for 2. 
implementation, if not currently
Explanation worksheet that explains the importance of each item scored, including 3. 
references
These items have been adapted from Tuberculosis Care and Control in Refugee and Displaced 
Populations: an Interagency Field Manual (1) among other references (see explanations).
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Write the item’s score in the last column (if yes met, give 1 point; if not met, give 0 points)
Item 
No.
Description
Score
Yes = 1
No = 0
Criteria for Implementation
1 Foresee security and stability for at least 6 months
2 National data indicate TB is an important problem
3 Acute or emergency phase is over (mortality is <1 per 10,000 population per day)
4 Basic water, shelter, food and sanitation needs are met 
5 Essential clinical services and basic drugs for common illnesses are available
6
Health services are accessible to enough of the population so that persons with 
symptoms suggestive of TB can be identified and appropriately investigated or 
referred
7 Sufficient funding is available for 12 months
Components Needed
8 Received political commitment at relevant levels of leadership
9 Developed memorandum of understanding with implementing partner’s TB program coordinator and lead health agency (e.g., MOH, WHO, or UNHCR)
10 Raised awareness in and received support from both host and displaced community
11 Used National TB Program as a resource in TB programming
12 Estimated staffing and training requirements (job descriptions, recruitment, training needs)
13 Plannned for patient accommodation, such as for intensive phase and other patients that require hospitalization as per determined criteria
14 Assessed lab resources 
15 Defined supervision system 
16 Assessed physical infrastructure
17 Established recording system
18 Established monitoring and evaluation of the program
Financial Needs
19 Estimated number of patients requiring TB treatment in the first year (plus 6 months) 
20 Determined health staff salaries
21 Estimated drugs and other medical supply requirements and costs
22 Estimated laboratory equipment and reagents requirements and costs
23 Estimated transport requirements for staff and supplies 
24 Estimated physical infrastructure costs including housing for patients and pharmacy
25 Estimated generator and fuel costs (if not already in place)
26 Identified training infrastructure needs and estimated costs 
27 Identified needs and estimated costs of recording system
Drug, Reagent, and Equipment Needs
28 Identified drug and materials procurement officer 
29 Identified potential suppliers and costs 
30 Estimated time from placing the order to arrival of drugs 
31 Procured suitable storage facilities 
32 Purchased drugs and supplies, including lab supplies
33 Put in place drug stock management system 
A Total Score
Program Implementation Evaluation Worksheet
Site     Country     Date
                 dd/mm/yy
58
Program Implementation Scoring Guide
Score/Rating Guide
Total Score from previous page (A)
Range Rating Suggested Time Until Implementation
30-33 (>=90%) Excellent Implementation now
25-29 (75%-89%) Good Reevaluate for implementation in 3-6 months
17-24 (50%-74%) Poor Reevaluate for implementation in 6-11 months
<=16 (<=49%) Failed Reevaluate for implementation in 12-18 months
59
Item 
No.
Explanation
 Criteria for Implementation
1-7
Because of concern about creating drug-resistant cases of TB and length of treatment, a TB 
control program should not be implemented unless stability in security, funding, basic needs 
of daily living, and basic clinical services are already implemented. Funding for 12 months is 
needed to complete treatment for the starting cohort; however, a total commitment of at least 
18 months is better (1, 20).
Components/Needed
8-10
Political commitment and awareness at all levels are critical and a memorandum of 
understanding or agreement can help ensure this as well as ensure completion of therapy in 
the event of repatriation or other movement.
11
The National TB Program (NTP) of the host country should be involved and contribute to the 
development and implementation of the TB control program. In addition, staff should be familiar 
with the regimen of the country of origin with the hope of repatriation if clinical conditions are 
suitable in country of origin (if not, complete therapy in host country).
12
Estimates of staffing and training requirements (job descriptions, recruitment, training needs):
1 TB coordinator per 50,000 population served A 2008 article from South Africa cited in •	
the methods for a health center (21):
1 full-time professional nurse or nurse assistant•	
1 doctor available at any point during clinic hours •	
1 half-time general clinic assistant•	
1 clerk available at any point during clinic hours.•	
13 A small number of very ill patients and a potentially large number of patients living at a distance will need accommodations or during intensive phase of treatment.
14-16 Determine human, material, and laboratory resource needs and cost. A source of quality control for the laboratory is also important (contact the NTP about this possibility).
17-18 Use the STOP TB strategy or other standardized templates (20 and WHO online resources, page 43). Use NTP counterparts for monitoring and evaluating. 
Financial Needs
19-27
Assessing TB burden among the population, using incident data from the population’s country 
of origin if possible, will provide a baseline for staffing, drug, supplies, laboratory, logistics, and 
other needs. If country-of-origin data are not available, use host-country data. TB incidence 
rates will provide an idea of numbers of staff, drugs, supplies, etc. needed. 
Drug, Reagent and Equipment Needs
28-33
Drug and materials procurement officer has been identified. Use TB burden among the 
population to estimate baseline amount of drugs and other supplies. Besides an adequate lab, 
drug procurement, storage, and stock management are essential to a well-functioning program. 
Program Implementation Explanation Worksheet
Site     Country     Date
                 dd/mm/yy
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